A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)

A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer

This is a multicenter, Phase II, randomized, controlled, open label trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with bevacizumab and paclitaxel in patients who have not previously received chemotherapy for locally recurrent or metastatic breast cancer.

Study Overview

• Status: Terminated
• Conditions: Metastatic Breast Cancer
• Intervention / Treatment: Drug: bevacizumab; Drug: paclitaxel; Drug: sunitinib

• Study Type: Interventional
• Enrollment (Actual): 46
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Signed Informed Consent Form
• Histologically or cytologically confirmed adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease
• Age ≥ 18 years
• Adequate left ventricular function at study entry, defined as an Left Ventricular Ejection Fraction (LVEF) > 50% by either Multi Gated Acquisition(MUGA) scan or Electrocardiogram (ECHO)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Ability and willingness to comply with study and follow-up procedures

Exclusion Criteria:

• Unknown HER2 status or known HER2-positive status
• Prior chemotherapy for locally recurrent or metastatic disease
• Prior hormonal therapy within 2 weeks prior to Day 1
• Prior adjuvant or neoadjuvant taxane chemotherapy within 12 months prior to Day 1
• Prior adjuvant or neoadjuvant non-taxane chemotherapy within 6 months prior to Day 1
• For patients who have received recent radiotherapy, ongoing Grade ≥ 3 acute toxicity
• Patients with brain metastasis on full dose anticoagulation therapy
• Life expectancy of < 12 weeks
• Current, recent (within 4 weeks of Day 1), or planned participation in an experimental drug study
• Inadequate organ function within 28 days prior to Day 1
• Untreated abnormal thyroid function tests
• Uncontrolled serious medical or psychiatric illness
• Active infection requiring IV antibiotics at enrollment or randomization
• History of other malignancies within 5 years prior to Day 1 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix
• Inadequately controlled hypertension
• Prior history of hypertensive crisis or hypertensive encephalopathy
• New York Heart Association (NYHA) Class II or greater CHF
• History of myocardial infarction or unstable angina within 12 months prior to Day 1
• History of stroke or transient ischemic attack within 12 months prior to Day 1
• Known central nervous system (CNS) disease except for treated brain metastasis
• Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1
• History of hemoptysis within 1 month prior to Day 1
• Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study
• Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
• History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1
• Serious, non-healing wound, active ulcer, or untreated bone fracture
• Proteinuria at screening, as demonstrated by a urine protein/creatinine ratio of ≥ 1.0 at screening
• Known hypersensitivity to any component of bevacizumab or sunitinib
• Pregnancy (positive pregnancy test) or lactation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1	Drug: bevacizumab; Intravenous repeating dose; Drug: paclitaxel; Intravenous repeating dose; Drug: sunitinib; Oral repeating dose
Placebo Comparator: 2	Drug: bevacizumab; Intravenous repeating dose; Drug: paclitaxel; Intravenous repeating dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Best Response	The best overall response is the best response, per the Response Evaluation Criteria In Solid Tumors (RECIST) criteria, recorded from randomization until disease progression/recurrence (includes both confirmed and unconfirmed responses). Although the original primary outcome was progression-free survival, there was insufficient data available to report on that outcome.	From randomization until disease progression/recurrence (by patient)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serious Adverse Events (SAEs)	All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0. An SAE is defined as an adverse event that results in death, is life threatening, requires hospitalization, results in significant disability, results in birth defect, or is considered a significant medical event by the investigator	30 days following the last administration of study treatment
Grade ≥ 3 Adverse Events (AEs)	All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0. Grading: 1=Mild AE; 2=Moderate AE; 3=Severe AE; 4=Life-threatening or disabling AE; 5=Death related to AE	30 days following the last administration of study treatment
Adverse Events Leading to Death	All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0	30 days following the last administration of study treatment
Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction	All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0	30 days following the last administration of study treatment
Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption	All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0	30 days following the last administration of study treatment

Collaborators and Investigators

• Sponsor: Genentech, Inc.
• Investigators: Study Director: Jai Balkissoon, M.D., Genentech, Inc.

Study record dates

Study Major Dates

• Study Start: March 1, 2007
• Primary Completion (Actual): May 1, 2008

Study Registration Dates

• First Submitted: February 9, 2007
• First Submitted That Met QC Criteria: February 9, 2007
• First Posted (Estimate): February 13, 2007

Study Record Updates

• Last Update Posted (Estimate): December 3, 2009
• Last Update Submitted That Met QC Criteria: November 17, 2009
• Last Verified: November 1, 2009

More Information

Terms related to this study

• Keywords: Breast Cancer; Avastin; Sutent; MBC
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Antineoplastic Agents, Immunological; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Protein Kinase Inhibitors; Paclitaxel; Sunitinib; Bevacizumab
• Other Study ID Numbers: AVF4057g